Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 4Recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Thoracic 2

Conditions

Brain Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Meningeal Carcinomatosis 2

Interventions

Temozolomide 163Radiosurgery 129Radiotherapy 107Bevacizumab 98Magnetic Resonance Spectroscopy 75Carboplatin 48Surgical Procedures, Operative 35pembrolizumab 34Radiation 34Etoposide 34Nivolumab 33Irinotecan 33Cyclophosphamide 33Erlotinib Hydrochloride 31Carmustine 28Trastuzumab 25Lomustine 25Cisplatin 25Ipilimumab 24Filgrastim 23Mental Status and Dementia Tests 21Magnetic Resonance Imaging 21Aminolevulinic Acid 21Vincristine 20Surveys and Questionnaires 19Capecitabine 19Topotecan 18Specimen Handling 18Pemetrexed 18Radiotherapy, Intensity-Modulated 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Brain Neoplasms × aumolertinib × CNS × Clear all
NCT05768490 2023-03-14

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Sun Yat-sen University

Phase 3 Recruiting
232 enrolled
CNS

Brain Neoplasms

NCT04778800 2021-08-31

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Henan Cancer Hospital

Phase NA Unknown
60 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Unknown
54 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04905550 2021-06-02

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Chongqing University Cancer Hospital

Phase 2 Unknown
50 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04643847 2020-11-25

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

First People's Hospital of Hangzhou

Phase 2 Unknown
47 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡